A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers
NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.
• Able to provide informed consent
• Huntingtin gene expansion carrier with \>= 39 CAG repeats
• Absence of unequivocal motor signs of HD - that is, UHDRS
• Diagnostic Confidence Level needs to be \<4 upon enrolment
• Expected to develop clinical HD within 10 years of trial enrolment using the Langbehn formula
• Availability of an informant for corroborative history
• Negative serum pregnancy test for women of childbearing potential
• If of childbearing potential, is able and agrees to remain abstinent or use adequate contraceptive methods
• Ability to tolerate MRI scans
• Ability to tolerate blood draws
• Able to comply with all study protocol requirements, according to the investigators judgement
• In the opinion of the investigator, medically, psychiatrically and neurologically stable at the time of enrolment